J&J collaborations

Johnson & Johnson Innovative Medicine and Multiple Myeloma

Johnson & Johnson Innovative Medicine’s goal is to fundamentally alter the way cancer is understood, diagnosed and managed. We are committed to finding innovative ways to fight cancer, including for smouldering and active multiple myeloma, and our primary efforts focus on treatment and prevention solutions.

We are driven by our commitment to patients, working side-by-side with healthcare stakeholders, to offer solutions based on trust and transparency. Below are a number of Johnson & Johnson Innovative Medicine’s initiatives that you may find interesting or helpful.

My Myeloma - Ready for the Steps Ahead

My Myeloma - Ready for the Steps Ahead is a documentary that captures the journey of multiple myeloma patients from the Central European and Baltics region. It was filmed in partnership with multiple myeloma patient organisations from Hungary, Croatia, Slovakia, Serbia and Slovenia. It is a heartfelt tribute to the patients, patient organisations and healthcare professionals who have battled tirelessly against this disease.

References

[1]

Global Patient and Carer Experience Survey. (2021). Available at: https://www.clladvocates.net/wp-content/uploads/2023/09/Global-Leukemia-Experience-Survey_Full-Report.pdf. Last accessed: November 2024.

[2]

Alu, Aqu et al. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. Journal of Hematology & Oncology. 2022 Oct;15:138.

[3]

Tam CS, et al. Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial. Curr Med Res Opin. 2023 Sep:1-7.

[4]

Eichhorst B, et al. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024;35(9):762-768.

[5]

DrugBank Online. Warfarin. Available at: https://go.drugbank.com/drugs/DB00682. Last accessed: November 2024.

[6]

Lipsky A, et al. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020 Dec;2020(1):336-345.

[7]

Cancer Research UK. Ibrutinib (Imbruvica). Available at: https://www.cancerresearchuk.org/about-cancer/treatment/drugs/ibrutinib. Last accessed: November 2024.

[8]

NHS Inform. Diarrhoea. Available at: https://www.nhsinform.scot/illnesses-and-conditions/stomach-liver-and-gastrointestinal-tract/diarrhoea/. Last accessed: November 2024.

[9]

Macmillan Cancer Support. Ibrutinib (Imbruvica). Available at: https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/ibrutinib. Last accessed: November 2024.

[10]

Quartermaine C, et al. (2023). Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology, 5(5), pp.570–590.

[11]

Zeynep Tuğba Güven. CLL-256 Monocytosis Developing in the Course of Chronic Lymphocytic Leukemia: Case Report. 2024;24;Sup 1: S349-S350.

[12]

Valla K, et al. Atrial Fibrillation: Considerations for the Use of BTK Inhibitors. Cancer Network Oncology. 2018 Nov; 32(11):574-575.

Get In Touch